The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives

被引:2
作者
de Hora, Mark [1 ,2 ]
Heather, Natasha [1 ,2 ]
Webster, Dianne [1 ,2 ]
Albert, Benjamin [2 ]
Hofman, Paul [3 ]
机构
[1] Auckland City Hosp, LabPlus, Newborn Screening, Specialist Chem Pathol, Auckland, New Zealand
[2] Univ Auckland, Liggins Inst, Auckland, New Zealand
[3] Univ Auckland, Liggins Inst, Clin Res Unit, Auckland, New Zealand
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
congenital adrenal hyperplasia; newborn screening; steroid profiling; bloodspots; LCMSMS congenital adrenal hyperplasia; LCMSMS; 21-HYDROXYLASE DEFICIENCY; BACKDOOR PATHWAY; BIOLOGICAL SAMPLES; STEROID PROFILE; 17-ALPHA-HYDROXYPROGESTERONE; MS/MS; QUANTIFICATION; DERIVATIZATION; METABOLISM; TIER;
D O I
10.3389/fendo.2023.1226284
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Newborn screening for congenital adrenal hyperplasia using 17-hydroxyprogesterone by immunoassay remains controversial despite screening been available for almost 40 years. Screening is confounded by poor immunoassay specificity, fetal adrenal physiology, stress, and illness which can result in a large number of false positive screening tests. Screening programmes apply higher screening thresholds based on co-variates such as birthweight or gestational age but the false positive rate using immunoassay remains high. Mass spectrometry was first applied to newborn screening for congenital adrenal hyperplasia over 15 years ago. Elevated 17-hydroxprogesterone by immunoassay can be retested with a specific liquid chromatography tandem mass spectrometry assay that may include additional steroid markers. Laboratories register with quality assurance programme providers to ensure accurate steroid measurements. This has led to improvements in screening but there are additional costs and added laboratory workload. The search for novel steroid markers may inform further improvements to screening. Studies have shown that 11-oxygenated androgens are elevated in untreated patients and that the adrenal steroidogenesis backdoor pathway is more active in babies with congenital adrenal hyperplasia. There is continual interest in 21-deoxycortisol, a specific marker of 21-hydroxylase deficiency. The measurement of androgenic steroids and their precursors by liquid chromatography tandem mass spectrometry in bloodspots may inform improvements for screening, diagnosis, and treatment monitoring. In this review, we describe how liquid chromatography tandem mass spectrometry has improved newborn screening for congenital adrenal hyperplasia and explore how future developments may inform further improvements to screening and diagnosis.
引用
收藏
页数:8
相关论文
共 55 条
[1]   The backdoor pathway to dihydrotestosterone [J].
Auchus, RJ .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (09) :432-438
[2]   Adrenal C11-oxy C21 steroids contribute to the C11-oxy C19 steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone [J].
Barnard, Lise ;
Gent, Rachelle ;
van Rooyen, Desmare ;
Swart, Amanda C. .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 174 :86-95
[3]   Wisconsin's Screening Algorithm for the Identification of Newborns with Congenital Adrenal Hyperplasia [J].
Bialk, Eric R. ;
Lasarev, Michael R. ;
Held, Patrice K. .
INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2019, 5 (03)
[4]   Determination of a steroid profile in heel prick blood using LC-MS/MS [J].
Boelen, Anita ;
Ruiter, An F. C. ;
Claahsen-van der Grinten, Hedi L. ;
Endert, Erik ;
Ackermans, Mariette T. .
BIOANALYSIS, 2016, 8 (05) :375-384
[5]   A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry [J].
Caron, Patrick ;
Turcotte, Veronique ;
Guillemette, Chantal .
JOURNAL OF CHROMATOGRAPHY A, 2021, 1650
[6]   Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test [J].
Cavarzere, Paolo ;
Camilot, Marta ;
Palma, Laura ;
Lauriola, Silvana ;
Gaudino, Rossella ;
Vincenzi, Monica ;
Antoniazzi, Franco ;
Teofoli, Francesca ;
Piacentini, Giorgio .
HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (03) :255-263
[7]   Congenital Adrenal Hyperplasia and the Second Newborn Screen [J].
Chan, Christine L. ;
McFann, Kim ;
Taylor, Laura ;
Wright, Daniel ;
Zeitler, Philip S. ;
Barker, Jennifer M. .
JOURNAL OF PEDIATRICS, 2013, 163 (01) :109-U499
[8]   Efficiency of Neonatal Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency in Children Born in Mainland France Between 1996 and 2003 [J].
Coulm, Benedicte ;
Coste, Joel ;
Tardy, Veronique ;
Ecosse, Emmanuel ;
Roussey, Michel ;
Morel, Yves ;
Carel, Jean-Claude .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2012, 166 (02) :113-120
[9]   Evaluation of a New Laboratory Protocol for Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand [J].
de Hora, Mark R. ;
Heather, Natasha L. ;
Webster, Dianne R. ;
Albert, Benjamin B. ;
Hofman, Paul L. .
INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2022, 8 (04)
[10]   Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening [J].
De Jesus, Victor R. ;
Simms, David A. ;
Schiffer, Jarad ;
Kennedy, Meredith ;
Mei, Joanne V. ;
Hannon, W. Harry .
CLINICA CHIMICA ACTA, 2010, 411 (21-22) :1684-1687